However, the role of PD-L1 tumor expression as predictor of immunotherapy response is currently debating, due to positive ORRs reported in clinical studies in patients carrying PD-L1 negative tumors (ACC cases not included) [29]. The gene discussed is CD274; the disease is adrenal cortex carcinoma.